17689-66-6

Basic information

• Product Name: 3-hydroxy-3-methylbutyl 4-methylbenzenesulfonate
• Synonyms: 3-hydroxy-3-methylbutyl 4-methylbenzenesulfonate
• CAS NO: 17689-66-6
• Molecular Formula: C₁₂H₁₈O₄S
• Molecular Weight: 258.34
• Mol File: 17689-66-6.mol
• Article Data: 30

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-hydroxy-3-methylbutyl 4-methylbenzenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 3-hydroxy-3-methylbutyl 4-methylbenzenesulfonate(17689-66-6)
• EPA Substance Registry System: 3-hydroxy-3-methylbutyl 4-methylbenzenesulfonate(17689-66-6)

Safety Data

• Hazardous Substances Data: 17689-66-6(Hazardous Substances Data)

Usage

General Description

3-Hydroxy-3-methylbutyl 4-methylbenzenesulfonate is a chemical compound that belongs to the class of sulfonate esters. It is used primarily as a surfactant and emulsifier in a variety of industrial and household products, including detergents, personal care products, and cleaning agents. It is known for its ability to reduce surface tension and enhance the solubility and dispersibility of other substances. Additionally, it is valued for its stability and compatibility with a wide range of other chemicals. However, the compound should be handled with caution due to its potential irritant properties, and proper safety measures should be taken when using products containing this chemical.

Upstream product

• 2568-33-4 3-methyl-butane-1,3-diol 
• 98-59-9 p-toluenesulfonyl chloride 
• 106948-09-8 (R)-3,3-dimethyloxiranemethanol 4-methylbenzenesulfonate 

Downstream Products

• 1030848-58-8 methyl 1-[4-(3-hydroxy-3-methylbutoxy)phenyl]-8-methyl-1,2,3,4-tetrahydroquinoline-7-carboxylate 
• 10572-18-6 3-methyl-1-(4-nitrophenoxy)butan-3-ol 

Relevant articles and documents

Achieving in Vivo Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders

Deregulation of the transcriptional repressor BCL6 enables tumorigenesis of germinal center B-cells, and hence BCL6 has been proposed as a therapeutic target for the treatment of diffuse large B-cell lymphoma (DLBCL). Herein we report the discovery of a series of benzimidazolone inhibitors of the protein-protein interaction between BCL6 and its co-repressors. A subset of these inhibitors were found to cause rapid degradation of BCL6, and optimization of pharmacokinetic properties led to the discovery of 5-((5-chloro-2-((3R,5S)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (CCT369260), which reduces BCL6 levels in a lymphoma xenograft mouse model following oral dosing.

2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS

Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) cardiovascular disease; (ii) metabolic disorders; (iii) diseases, disorders, and conditions associated with vascular pathology; and (iv) organ failure; (v) diseases, disorders, and conditions associated with infections (e.g., microbial infections); and (vi) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include pulmonary hypertension (e.g., PAH); heart failure; type II diabetes; renal failure; sepsis; and systemic hypertension.